The FDA has approved Eli Lilly’s Baqsimi nasal powder 3 mg, making it the first needleless glucagon therapy OK’d by the agency for the emergency treatment of severe hypoglycemia.

The drug is the first and only nasally-administrated glucagon treatment indicated for diabetic patients aged four and above experiencing severe hypoglycemia, a dangerously low level of blood sugar.

The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly.